Salonpas Lidocaine Plus Liquid
NDC Package 55328-901-03
Package Information
Salonpas Lidocaine Plus (benzyl alcohol, lidocaine hydrochloride) liquids is adults and children 12 years of age and over:clean and dry affected areaapply to affected area not more than 3 to 4 times dailyChildren under 12 years of age:consult a doctor. This formulation utilizes a liquid delivery system. Marketed by Hisamitsu America, Inc., this product is identified by NDC 55328-901 and is authorized under FDA application M017.
Identification & Billing
- RxCUI: 1943537 - benzyl alcohol 10 % / lidocaine HCl 4 % Topical Solution
- RxCUI: 1943537 - benzyl alcohol 0.1 ML/ML / lidocaine hydrochloride 40 MG/ML Topical Solution
Clinical Specifications
- Percutaneous - Administration through the skin.
- Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
- Transdermal - Administration through the dermal layer of the skin to the systemic circulation by diffusion.
Regulatory & Marketing
Hierarchy Structure
- 55328 - Hisamitsu America, Inc.
- 55328-901 - Salonpas Lidocaine Plus
- 55328-901-03 - 1 TUBE in 1 BOX / 80 g in 1 TUBE
- 55328-901 - Salonpas Lidocaine Plus
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55328-901-03 identifies a specific commercial package of 1 tube in 1 box / 80 g in 1 tube of Salonpas Lidocaine Plus, a human over the counter drug labeled by Hisamitsu America, Inc.. This liquid is formulated for percutaneous; topical; transdermal use and contains benzyl alcohol; lidocaine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hisamitsu America, Inc. on September 01, 2017. The current certification is valid through December 31, 2026.
How is this Hisamitsu America, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55328090103. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.